UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 201

Sortiert nach

Machine learning for comprehensive forecasting of Alzheimer's Disease progression

Scientific reports, 2019-09, Vol.9 (1), p.13622-14, Article 13622

2019

Volltextzugriff (PDF)

EN3-4. Real-world characteristics and outcomes of advanced NSCLC patients with Exon 19 or 21 EGFR mutations

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.552-552

2021

Volltextzugriff (PDF)

ENP-1. Outcomes of Treated Patients with EGFR-mutated Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Exon 19 Deletions or L858R Substitution (Exon 21) Mutations : A Systematic Literature Review

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.554-554

2021

Volltextzugriff (PDF)

High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs

Journal of Atherosclerosis and Thrombosis, 2015/12/01, Vol.22(12), pp.1287-1304

2015

Volltextzugriff (PDF)

GL2-5. RELAY Global Phase 3 Trial in Untreated Metastatic EGFR-Mutated NSCLC : Liquid Biopsy Study Update

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.493-493

2022

Volltextzugriff (PDF)

2105 UCSF AutoImmunoProfiler – Understanding the Immunomes of Autoimmune diseases

Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A111-A112

2022

Volltextzugriff (PDF)

EN3-2. Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001 : A phase 1/2 trial of selpercatinib

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.551-551

2021

Volltextzugriff (PDF)

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment : a Japanese claims database study

Journal of Clinical and Experimental Hematopathology, 2023, Vol.63 (4), p.219-229

2023

Volltextzugriff (PDF)

The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy

Japanese Journal of Lung Cancer, 2019-12, Vol.59 (7), p.1140-1150

2019

Volltextzugriff (PDF)

Tadalafil, a Long-Acting Inhibitor of PDE5, Improves Pulmonary Hemodynamics and Survival Rate of Monocrotaline-Induced Pulmonary Artery Hypertension in Rats

Journal of Pharmacological Sciences, 2009, Vol.111(3), pp.235-243

2009

Volltextzugriff (PDF)

O65-4. Interim analysis of a post-marketing safety study of selpercatinib in Japanese patients with NSCLC

Japanese Journal of Lung Cancer, 2023-10, Vol.63 (5), p.558-558

2023

Volltextzugriff (PDF)

ES-2 EGFR変異陽性肺癌患者に対するgefitinibとpemetrexed併用療法の比較第II相試験 : Translational research

肺癌, 2017-09, Vol.57 (5), p.352-352

2017

Volltextzugriff (PDF)

Actavis v. Lilly – Pemetrexed: Decision of the Supreme Court 12 July 2017 – Case No. [2017] UKSC 48

IIC - International Review of Intellectual Property and Competition Law, 2018, Vol.49 (1), p.104-105

2018

Volltextzugriff (PDF)

PS-2. RELAY Japan subset : Global Ph3 study of erlotinib + ramucirumab or placebo in first-line metastatic NSCLC with EGFR mutations

Japanese Journal of Lung Cancer, 2019-11, Vol.59 (6), p.536-537

2019

Volltextzugriff (PDF)

Responses to the Letter to the Editor "Does growth-hormone treatment affect patients with and without a mitochondrial disorder differentially ?" (Vol. 27, No. 2, p. 107 - 108, 2018)

Clinical Pediatric Endocrinology, 2018-07, Vol.27 (3), p.201-202

2018

Volltextzugriff (PDF)

ES-1 IV期非扁平上皮非小細胞肺癌患者に対するネシツムマブとペムブロリズマブ併用療法の有効性及び安全性

肺癌, 2017-09, Vol.57 (5), p.352-352

2017

Volltextzugriff (PDF)

Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Clinical Pediatric Endocrinology, 2017-10, Vol.26 (4), p.229-241

2017

Volltextzugriff (PDF)

O-52 Randomized trial : gefitinib w/wo pemetrexed as 1L therapy for EGFR-mutated NS NSCLC in East-Asia

Japanese Journal of Lung Cancer, 2015-10, Vol.55 (5), p.431-431

2015

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

ENDOCRINE JOURNAL, 2009, Vol.56 (8), p.951-962

2009

Volltextzugriff (PDF)

S1-1 First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer : A randomised, phase 3 trial

Japanese Journal of Lung Cancer, 2014-10, Vol.54 (5), p.272-272

2014

Volltextzugriff (PDF)

IP-113_G. Ramucirumab (RAM) as 2L Treatment in Patients (pts) with Advanced HCC following 1L Therapy with Sorafenib : Patient-Focused Outcome (PFO) Results from the Phase 3 REACH Study

Journal of Japanese Society of Gastroenterology, 2018-09, Vol.115 (suppl-2), p.844-844

Reigetsu Yoshikawa

2018

Volltextzugriff (PDF)

Prediction of roller compacted ribbon solid fraction for quality by design development

Powder technology, 2011-11, Vol.213 (1), p.1-13

2011

Volltextzugriff (PDF)

S9-1 REVEL : Ramucirumab-Docetaxel vs Placebo-Docetaxel in Second-line Stage IV Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer, 2014-10, Vol.54 (5), p.285-285

2014

Volltextzugriff (PDF)

Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies

Biochemical pharmacology, 2018-09, Vol.155, p.61-70

2018

Volltextzugriff (PDF)

Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment

ENDOCRINE JOURNAL, 2017-04, Vol.64 (4), p.449-456

2017

Volltextzugriff (PDF)

1 – 25 von 201

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(166)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(145)
Japanisch
(76)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(75)
Life Sciences & Biomedicine
(70)
Animals
(47)
Biological And Medical Sciences
(34)
Female
(28)
Humans
(28)
Fundamental And Applied Biological Sciences. Psychology
(24)
Male
(23)
Biochemistry & Molecular Biology
(14)
Medical Sciences
(13)
Adult
(10)
Mice
(10)
Pharmacology & Pharmacy
(10)
Physical Sciences
(10)
Food Science & Technology
(9)
Agriculture
(8)
Antibioticos
(8)
Antibiotique
(8)
Chemistry
(8)
Vertebrates
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Machine learning for comprehensive forecasting of Alzheimer's Disease progression

EN3-4. Real-world characteristics and outcomes of advanced NSCLC patients with Exon 19 or 21 EGFR mutations

ENP-1. Outcomes of Treated Patients with EGFR-mutated Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Exon 19 Deletions or L858R Substitution (Exon 21) Mutations : A Systematic Literature Review

High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs

GL2-5. RELAY Global Phase 3 Trial in Untreated Metastatic EGFR-Mutated NSCLC : Liquid Biopsy Study Update

2105 UCSF AutoImmunoProfiler – Understanding the Immunomes of Autoimmune diseases

EN3-2. Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001 : A phase 1/2 trial of selpercatinib

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment : a Japanese claims database study

Tadalafil, a Long-Acting Inhibitor of PDE5, Improves Pulmonary Hemodynamics and Survival Rate of Monocrotaline-Induced Pulmonary Artery Hypertension in Rats

O65-4. Interim analysis of a post-marketing safety study of selpercatinib in Japanese patients with NSCLC

ES-2 EGFR変異陽性肺癌患者に対するgefitinibとpemetrexed併用療法の比較第II相試験 : Translational research

Actavis v. Lilly – Pemetrexed: Decision of the Supreme Court 12 July 2017 – Case No. [2017] UKSC 48

PS-2. RELAY Japan subset : Global Ph3 study of erlotinib + ramucirumab or placebo in first-line metastatic NSCLC with EGFR mutations

Responses to the Letter to the Editor "Does growth-hormone treatment affect patients with and without a mitochondrial disorder differentially ?" (Vol. 27, No. 2, p. 107 - 108, 2018)

ES-1 IV期非扁平上皮非小細胞肺癌患者に対するネシツムマブとペムブロリズマブ併用療法の有効性及び安全性

Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

O-52 Randomized trial : gefitinib w/wo pemetrexed as 1L therapy for EGFR-mutated NS NSCLC in East-Asia

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes

S1-1 First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer : A randomised, phase 3 trial

IP-113_G. Ramucirumab (RAM) as 2L Treatment in Patients (pts) with Advanced HCC following 1L Therapy with Sorafenib : Patient-Focused Outcome (PFO) Results from the Phase 3 REACH Study

Prediction of roller compacted ribbon solid fraction for quality by design development

S9-1 REVEL : Ramucirumab-Docetaxel vs Placebo-Docetaxel in Second-line Stage IV Non-Small Cell Lung Cancer

Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies

Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment

Suchergebnisse filtern